Targeted Graves Disease PBMC Collection for HLA Research

August 26, 2026

Why are targeted Graves disease PBMC cohorts important?

Graves disease is an autoimmune disorder in which the immune system stimulates the thyroid to produce excess thyroid hormone. The disease can also affect tissues surrounding the eyes, resulting in thyroid eye disease (TED), also called Graves orbitopathy.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, Graves disease likely develops through a combination of genetic susceptibility and environmental triggers. This makes access to well-characterized biological specimens important for research into disease mechanisms, biomarkers, patient stratification, and potential therapeutic targets.

For studies investigating a particular human leukocyte antigen (HLA) type, recruitment becomes especially complex. Researchers may need participants who satisfy several clinical and genetic requirements simultaneously, such as:

- A confirmed Graves disease diagnosis
- Thyroid eye disease or active orbitopathy
- A specific HLA type
- Defined thyroid hormone or antibody measurements
- Specimens processed according to a precise protocol

Because the target HLA type may occur in only a subset of the eligible population, researchers often need to screen a broader cohort before identifying qualifying donors.

What role does HLA play in Graves disease research?

Human leukocyte antigens help the immune system distinguish between the body’s own proteins and potentially harmful foreign substances. Variations within HLA genes have been studied for their possible relationship to autoimmune disease susceptibility and clinical presentation.

A 2023 systematic review of HLA in Graves disease and Graves orbitopathy found that reported associations can differ between populations and according to the genetic-typing methods used. These differences reinforce the importance of accurately defined cohorts, reliable HLA testing, and detailed clinical annotation when studying genetic associations.

Targeted collections can help sponsors investigate whether a particular HLA type is associated with disease biology, immune response, phenotype, or another study-specific endpoint. However, identifying donors with a target HLA type does not by itself establish a causal relationship with Graves disease or thyroid eye disease.

Why use PBMCs in autoimmune and biomarker research?

Peripheral blood mononuclear cells (PBMCs) include lymphocytes and monocytes that play central roles in immune activity. Depending on the research protocol, PBMCs may support applications such as:

- Immune-cell phenotyping
- Flow cytometry
- Genotyping
- Gene-expression analysis
- Biomarker discovery
- Functional immune assays
- Evaluation of cellular responses

Research has also used PBMCs to investigate immune-cell behavior in Graves disease, including B-cell responses to thyroid autoantigens. One recent single-cell sequencing study analyzed PBMC populations from patients with Graves disease to explore immune pathways involved in disease pathogenesis.

For these applications, the collection and processing protocol can materially affect specimen suitability. Sponsors may specify collection tubes, time-to-processing limits, isolation methods, cell counts, viability thresholds, cryopreservation procedures, storage conditions, and data requirements. Consistent execution is essential when specimens will be compared across donors or used in sensitive downstream assays.

The challenge: combining clinical and genetic eligibility criteria

A biopharmaceutical sponsor was investigating a specific HLA type and its potential relationship to Graves disease. The study required a narrowly defined patient population that included thyroid eye disease as a comorbidity and active orbitopathy at enrollment.

Recruitment therefore required more than identifying donors with a Graves disease diagnosis. Each prospective participant had to be evaluated against the sponsor’s clinical criteria before collection.

The program also required:

- PBMC processing according to detailed sponsor specifications
- Procedures designed to preserve cell viability
- T3 and T4 thyroid hormone measurements
- Graves disease diagnosis details
- Thyrotropin receptor antibody (TRAb) titers
- Post-collection testing for the specified HLA type

The combination of clinical phenotype, specimen-processing requirements, data collection, and HLA testing created a complex recruitment and operational challenge.

The solution: prospective recruitment with sponsor-defined processing

Boca Bio established a prospective collection program at a clinical site outside the United States. The program enrolled 10 donors who met the defined Graves disease, thyroid eye disease, and orbitopathy criteria.

PBMCs were isolated and processed according to the sponsor’s protocol. Clinical information collected for the study included T3 and T4 levels, diagnosis details, and TRAb titers.

After enrollment and specimen processing, donors were tested for the HLA type under investigation. This approach allowed the sponsor to evaluate the target genetic characteristic within a clinically relevant and highly characterized population..

Study results

Boca Bio completed the targeted prospective collection and enrolled 10 donors who satisfied the study criteria.

The program delivered:

- High-viability PBMC samples processed to sponsor specifications
- Prospective screening that incorporated thyroid eye disease and active orbitopathy requirements
- T3 and T4 levels, diagnosis details, and TRAb titers
- HLA testing for the specified genetic target
- Two donors who carried the target HLA type

The collection demonstrated the value of coordinating clinical screening, biospecimen processing, laboratory testing, and data capture within one prospective research program.

What can biopharma and diagnostics teams learn from this study?

Define the phenotype before recruitment begins

Terms such as thyroid eye disease, Graves orbitopathy, and active orbitopathy must be translated into clear eligibility and documentation requirements. Precise definitions help clinical sites screen participants consistently.

Assess the likely HLA frequency during feasibility

A narrowly defined HLA requirement can substantially affect the number of individuals who must be screened. Feasibility planning should consider the expected prevalence of the target type, the clinical criteria, geography, and the sponsor’s required sample count.

Align PBMC processing with downstream applications

Processing requirements should reflect the intended assay. Collection-to-processing time, isolation method, viability, cryopreservation, storage, and shipping conditions should be defined before enrollment.

Determine which clinical data are essential

Clinical annotation can improve the scientific value of PBMC specimens. Depending on the research question, relevant data may include thyroid hormone levels, TRAb titers, diagnosis history, disease activity, treatment status, medications, comorbidities, and demographic information.

Plan for screening attrition

Not every clinically eligible donor will carry the target HLA type. A prospective protocol should account for the difference between donors screened, donors enrolled, samples processed, and donors confirmed as HLA-positive.

Supporting targeted autoimmune-disease research

Boca Bio supports biopharmaceutical and diagnostics teams with prospective biospecimen collection, sponsor-defined clinical screening, PBMC processing, laboratory testing, clinical data collection, and biospecimen storage.

By coordinating these components, researchers can access specimens aligned with specific disease phenotypes, genetic characteristics, processing requirements, and downstream research objectives.

Planning an autoimmune, biomarker, or HLA-focused study? Contact Boca Bio to discuss your target population, biospecimen requirements, clinical data, and processing protocol.

Frequently Asked Questions (FAQs)

Share this Post